Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Authors : Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF
Year : 2017
Journal : BMJ Open
Volume : 7(11)
Pages : e017075

Rôle de corticostéroïdes dans le cancer de la prostate. Effet bénéfique ou néfaste ?

Authors : Martinez C, Sideris S, Roumeguere T, Van Velthoven R, Awada A, Costante G, Gil T
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Nutrition et prévention du cancer : changer les mentalités

Authors : Awada A
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Foreword

Authors : Awada A
Year : 2016
Journal : EMJ Oncology
Volume : 41
Pages : 11

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Authors : Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, OKeeffe B, Shapiro GI, Winer EP
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 160
Pages : 305-312

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors : Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000097

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Authors : Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27
Pages : 1021-7

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors.

Authors : Gil T, Sideris S, Aoun F, Van Velthoven R, Sirtaine N, Paesmans M, Ameye L, Awada A, Devriendt D, Peltier A
Year : 2016
Journal : Mol Clin Oncol
Volume : 5
Pages : 258-264

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.

Authors : Agarwal N, Machiels JP, Suárez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M
Year : 2016
Journal : Oncologist
Volume : 21(5)
Pages : 535-6

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Authors : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Year : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Authors : Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA
Year : 2016
Journal : JAMA Oncol
Volume : 2(12)
Pages : 1557-64

Learning from the tsunami" of immune checkpoint inhibitors in 2015."

Authors : Kourie HR, Awada G, Awada A
Year : 2016
Journal : Crit Rev Oncol Hematol
Volume : 101
Pages : 213-220

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.

Authors : Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 156(2)
Pages : 319-30

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

Authors : Twelves C, Jove M, Gombos A, Awada A
Year : 2016
Journal : Crit Rev Oncol Hematol
Volume : 100
Pages : 74-87

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice.

Authors : Lalami Y, Awada A
Year : 2016
Journal : Cancer Treat Rev
Volume : 43
Pages : 113-23

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Authors : Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27(4)
Pages : 342-8

p53 Reactivation by PRIMA-1 Met (APR-246) sensitises V600E/K BRAF melanoma to vemurafenib.

Authors : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sales F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Year : 2016
Journal : Eur J Cancer
Volume : 55
Pages : 98-110

Emerging Drugs Targeting Human Epidermal Growth Factor Receptor 2 (Her2) In The Treatment Of Breast Cancer.

Authors : Awada G, Gombos A, Aftimos P, Awada A
Year : 2016
Journal : Expert Opin Emerg Drugs
Volume : 21(1)
Pages : 91-101

Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients.

Authors : Sideris S, Aoun F, Martinez Chanza N, Latifyan S, Awada A, Costante G, Gil T
Year : 2016
Journal : J Endocrinol Invest
Volume : 39(7)
Pages : 729-38

Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

Authors : Kourie HR, Awada G, Awada A
Year : 2016
Journal : Future Oncol
Volume : 12(4)
Pages : 429-31